These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6992459)

  • 1. Inhibition of glucagon secretion by diphenylhydantoin in a patient with glucagonoma.
    Machina T; Marcus R; Levin SR
    West J Med; 1980 Apr; 132(4):357-60. PubMed ID: 6992459
    [No Abstract]   [Full Text] [Related]  

  • 2. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.
    Valverde I; Lemon HM; Kessinger A; Unger RH
    J Clin Endocrinol Metab; 1976 May; 42(5):804-8. PubMed ID: 178682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretory response and immunochemical heterogeneity of glucagon in plasma and tumor extracts of a patient with glucagonoma.
    Torre L; Vazquez JA; Blázquez E
    Horm Res; 1986; 23(3):159-66. PubMed ID: 3005153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inappropriate secretion of insulin by an islet cell adenoma. Trial treatment with diphenylhydantoin].
    Bricaire H; Luton JP; Wechsler B; Messing B; Halaby G
    Ann Med Interne (Paris); 1976 May; 127(5):403-7. PubMed ID: 189663
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and metabolic aspects of glucagonoma.
    Leichter SB
    Medicine (Baltimore); 1980 Mar; 59(2):100-13. PubMed ID: 6987481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glucagonoma syndrome--a manifestation of neoplastic process].
    Clszewska Z; Tyburska-Trebińska A
    Przegl Dermatol; 1980; 67(5):647-52. PubMed ID: 7005973
    [No Abstract]   [Full Text] [Related]  

  • 7. [Benign insulinoma. Efficacy of preoperative treatment for persistent hyperinsulinemia using a synthetic somatostatin analog].
    Esposito V; Esposito D; Lo Iudice G; Rispoli C; Verrillo A; D'Alessandro B
    Minerva Endocrinol; 1994 Mar; 19(1):33-7. PubMed ID: 8035768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glucagonoma].
    Shima K
    Horumon To Rinsho; 1971 Apr; 19(4):321-5. PubMed ID: 4939134
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
    Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ
    Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal.
    Holst JJ; Burcharth F; Kühl C
    Diabete Metab; 1980 Jun; 6(2):117-27. PubMed ID: 6997101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagonoma and pseudoglucagonoma syndrome.
    Echenique-Elizondo M; Tuneu Valls A; Elorza Orúe JL; Martinez de Lizarduy I; Ibáñez Aguirre J
    JOP; 2004 Jul; 5(4):179-85. PubMed ID: 15254346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of xylazine on plasma glucose, glucagon and insulin concentrations in sheep.
    Brockman RP
    Res Vet Sci; 1981 May; 30(3):383-4. PubMed ID: 7020020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of glucagon secretion by crude liver extract in conscious dogs.
    Kabadi UM
    Diabetes Res; 1993; 23(1):41-6. PubMed ID: 7924147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia.
    Hoff AO; Vassilopoulou-Sellin R
    Cancer; 1998 Apr; 82(8):1585-92. PubMed ID: 9554538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glucagonoma].
    Shima K
    Nihon Rinsho; 1974 Apr; 32(4):738-44. PubMed ID: 4152684
    [No Abstract]   [Full Text] [Related]  

  • 16. Amino acid, glucose, and lipid kinetics after palliative resection in a patient with glucagonoma syndrome.
    Bernstein M; Jahoor F; Townsend CM; Klein S
    Metabolism; 2001 Jun; 50(6):720-2. PubMed ID: 11398151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the metabolic action of glucagon in subjects undergoing anti-insulin therapy].
    Marugo M; Mortara R; Baiardi M; Giusti M; Motta A; Grimaldi GP
    Clin Ter; 1981 Mar; 96(6):579-92. PubMed ID: 7026132
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experimental and clinical studies on the secretory response of plasma glucagon after total pancreatectomy].
    Sudo T
    Nihon Geka Hokan; 1979 Mar; 48(2):217-32. PubMed ID: 399838
    [No Abstract]   [Full Text] [Related]  

  • 19. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a controlled trial.
    Perry-Keene DA; Larkins RG; Heyma P; Peter CT; Ross D; Sloman JG
    Clin Endocrinol (Oxf); 1980 Jun; 12(6):575-80. PubMed ID: 6994939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.